Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Patients with Posttransplant Myeloma.

ABSTRACT:

Purpose

In this study, the addition of ixazomib to lenalidomide maintenance post-autologous stem cell transplant (ASCT) in 64 patients with newly diagnosed multiple myeloma was evaluated on the basis of the observed benefit of lenalidomide-only maintenance in prior studies.

Patients and methods

Patients were started on maintenance therapy with lenalidomide and ixazomib within 60-180 days of stem cell infusion.

Results

Response rates deepened over time from baseline post-ASCT for 39 patients. The complete response (CR)/stringent CR rate was 43% and median overall survival was not reached with a median follow-up of 62 months (range, 25-82 months). Median PFS (mPFS) for all patients was 73 months and has not been reached for those with International Staging System (ISS)

SUBMITTER: Patel KK 

PROVIDER: S-EPMC9365361 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature